Redeye makes upward estimate revisions on the back of I-Tech’s solid Q1 figures. Delivering organic growth of 34% in the quarter confirms that Q4’23-figures was only a bump in the road. We argue that I-Tech is back on track with a solid financial outlook, as several customers starting to drive topline. The uncertainty regarding the EU BPR process continues to impact investor sentiment.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/